Therapy for Mycobacterium kansasii Infection: Beyond 2018

The current standard of care therapy for pulmonary Mycobacterium kansasii infection is isoniazid (300 mg/day), rifampin (600 mg/day), and ethambutol (15 mg/kg/day) for 12 months after achieving sputum culture negativity. Rifampin is the key drug in this regimen. The contribution of isoniazid is uncl...

Descripción completa

Detalles Bibliográficos
Autores principales: DeStefano, Michelle S., Shoen, Carolyn M., Cynamon, Michael H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166578/
https://www.ncbi.nlm.nih.gov/pubmed/30319580
http://dx.doi.org/10.3389/fmicb.2018.02271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166578/
https://www.ncbi.nlm.nih.gov/pubmed/30319580
http://dx.doi.org/10.3389/fmicb.2018.02271

Ejemplares similares